Subtrochanteric Pathological Femur Fracture in an HIV-Positive Patient on Tenofovir-based Antiretroviral Therapy: A Case Report and Review of the Literature

Overview

Journal J Orthop Case Rep

Specialty Orthopedics

Date 2023 May 5

PMID 37144071

Authors

Siddharth Choudhary

Karthick Rangasamy

Shankar Naidu

Ravinder Kaur Sachdeva

Aman Sharma

Affiliations

Soon will be listed here.

Abstract

Introduction: The population of people living with human immunodeficiency virus (HIV) and AIDS has increased and so is the incidence of fragility fractures in these patients. Multiple contributory factors are responsible for osteomalacia or osteoporosis in such patients such as a chronic inflammatory response to the HIV, highly active antiretroviral therapy (HAART) itself, and associated comorbidities. Tenofovir has also been reported to disrupt bone metabolism and causes fragility fractures.

Case Report: A 40-year-old HIV-positive female came to us with pain in her left hip and was unable to bear weight. She had a history of trivial fall. The patient has been taking tenofovir-associated HAART regimen for the past 6 years and has been compliant. She was diagnosed with a left-side transverse subtrochanteric closed femur fracture. Closed reduction and internal fixation was done using a proximal femur intramedullary nail (PFNA). The latest follow-up shows fracture union and good functional outcomes after treating osteomalacia, and HAART changed to a non-tenofovir regimen later.

Conclusion: Patients with HIV infection are prone to fragility fractures and periodic monitoring of their BMD, serum calcium, and vitamin D3 levels should be done for prevention and early diagnosis. More vigilance in patients receiving a tenofovir-associated HAART regimen is needed. Appropriate medical treatment needs to be started once any abnormality in the bone metabolic parameters is detected, and drugs like tenofovir need to be changed as it causes osteomalacia.

References

Rabenda V, Bruyere O, Reginster J . Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporos Int. 2010; 22(3):893-901. DOI: 10.1007/s00198-010-1469-x. View

Yang H, Beymer M, Suen S . Chronic Disease Onset Among People Living with HIV and AIDS in a Large Private Insurance Claims Dataset. Sci Rep. 2019; 9(1):18514. PMC: 6897968. DOI: 10.1038/s41598-019-54969-3. View

Triant V, Brown T, Lee H, Grinspoon S . Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008; 93(9):3499-504. PMC: 2567857. DOI: 10.1210/jc.2008-0828. View

Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A . Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int. 2007; 19(7):913-8. DOI: 10.1007/s00198-007-0524-8. View

Parsonage M, Wilkins E, Snowden N, Issa B, Savage M . The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med. 2005; 6(5):341-6. DOI: 10.1111/j.1468-1293.2005.00318.x. View

Carr A, Kerr S, Richardson R, Ebeling P, Pocock N, Rojas J . Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study. J Bone Miner Res. 2019; 34(12):2192-2197. DOI: 10.1002/jbmr.3834. View

Ansemant T, Mahy S, Piroth C, Ornetti P, Ewing S, Guilland J . Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients. BMC Infect Dis. 2013; 13:7. PMC: 3545895. DOI: 10.1186/1471-2334-13-7. View

Borges A, Hoy J, Florence E, Sedlacek D, Stellbrink H, Uzdaviniene V . Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Clin Infect Dis. 2017; 64(10):1413-1421. DOI: 10.1093/cid/cix167. View

Earle K, Seneviratne T, Shaker J, Shoback D . Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res. 2004; 19(5):714-21. DOI: 10.1359/jbmr.2004.19.5.714. View

10.

Premaor M, Compston J . People living with HIV and fracture risk. Osteoporos Int. 2020; 31(9):1633-1644. DOI: 10.1007/s00198-020-05350-y. View

11.

Mazziotti G, Canalis E, Giustina A . Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med. 2010; 123(10):877-84. DOI: 10.1016/j.amjmed.2010.02.028. View

12.

Jhaveri M, Mawad H, Thornton A, Mullen N, Greenberg R . Tenofovir-associated severe bone pain: I cannot walk!. J Int Assoc Physicians AIDS Care (Chic). 2010; 9(5):328-34. DOI: 10.1177/1545109710376595. View

13.

Das S, Bopitya S, Taha H, David L . Relationship between vitamin D, parathyroid hormone, bone mineral density, fracture and antiretroviral therapy in HIV patients. Recent Pat Antiinfect Drug Discov. 2014; 9(1):6-13. DOI: 10.2174/1574891x09666140609123138. View

14.

De Socio G, Fabbriciani G, Massarotti M, Messina S, Cecchini E, Marasini B . Hypophosphatemic Osteomalacia Associated with Tenofovir: a Multidisciplinary Approach is Required. Mediterr J Hematol Infect Dis. 2012; 4(1):e2012025. PMC: 3375688. DOI: 10.4084/MJHID.2012.025. View

15.

Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne C . Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol. 2009; 15(2):72-4. DOI: 10.1097/RHU.0b013e31819c20d8. View

16.

Saidenberg-Kermanach N, Souabni L, Prendki V, Prie D, Boissier M . Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. Joint Bone Spine. 2010; 78(3):306-8. DOI: 10.1016/j.jbspin.2010.11.007. View

17.

Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot D . Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A. 2010; 107(31):13848-53. PMC: 2922243. DOI: 10.1073/pnas.1003020107. View

18.

Haverkort M, van der Spek B, Lips P, Slieker W, Ter Heine R, Huitema A . Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature. Scand J Infect Dis. 2011; 43(10):821-6. DOI: 10.3109/00365548.2011.577805. View

19.

Van Rompay K, Brignolo L, Meyer D, Jerome C, Tarara R, Spinner A . Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004; 48(5):1469-87. PMC: 400569. DOI: 10.1128/AAC.48.5.1469-1487.2004. View

20.

Di Biagio A, Rosso R, Monteforte P, Russo R, Rovetta G, Viscoli C . Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. J Med Case Rep. 2009; 3:8136. PMC: 2737799. DOI: 10.4076/1752-1947-3-8136. View